New Research Puts Ketamine's Side Effect Profile Under the Microscope
A 2026 analysis published in Psychiatric Times takes a detailed look at the side effect profiles and discontinuation rates associated with NMDA receptor antagonists — the drug class that includes both IV ketamine and intranasal esketamine (Spravato) — in patients with treatment-resistant depression (TRD). The review synthesizes clinical data to compare how patients tolerate these medications over time and under what circumstances they stop treatment altogether.
For the growing number of Americans exploring ketamine therapy through online and telehealth platforms, this kind of research matters. It moves the conversation beyond whether ketamine works — a question the evidence has largely answered in favor — and into the more nuanced territory of what to realistically expect, how to prepare, and what distinguishes a well-run program from one that leaves patients without adequate support when side effects arise.
What the Research Actually Found
NMDA receptor antagonists, as a class, carry a well-documented set of transient side effects: dissociation, dizziness, nausea, elevated blood pressure, and perceptual disturbances during or shortly after administration. What the Psychiatric Times review adds to our understanding is how frequently these effects drive patients to discontinue treatment — and how that discontinuation rate compares across delivery formats and patient populations.
Discontinuation rates in clinical trials for esketamine (Spravato) have hovered in a meaningful range, with some studies showing that a notable subset of patients stop treatment during the induction phase due to tolerability concerns rather than lack of efficacy. IV ketamine, administered in controlled clinical settings, shows a broadly similar tolerability window, though the acute dissociative effects are often more pronounced given the infusion route and dosing flexibility.
Critically, the research underscores that side effects in this drug class are almost universally acute — meaning they occur during or immediately after treatment and resolve within hours. Serious adverse events are rare when appropriate screening and monitoring protocols are in place. This is a meaningful distinction for patients who may conflate the immediate, strange-feeling experience of a ketamine session with longer-term risk, when in fact the safety data is quite favorable under clinical supervision.
Why This Matters for Telehealth Ketamine Specifically
The telehealth ketamine landscape in 2026 spans a wide range of provider quality. At one end are rigorous, physician-led programs that conduct comprehensive psychiatric evaluations, screen for cardiovascular contraindications, coordinate with patients' existing mental health providers, and have structured protocols for managing adverse reactions. At the other end are platforms that prioritize speed and low-friction onboarding — sometimes at the expense of the safety infrastructure this research implicitly argues is necessary.
When discontinuation rates are elevated, it is rarely because ketamine simply doesn't work for a patient. More often, it reflects inadequate preparation: patients who weren't counseled on what dissociation feels like, who lacked a support person during their session, or whose anxiety about side effects wasn't addressed before they began. The clinical data on tolerability, read correctly, is an argument for better intake processes — not a reason to avoid treatment.
For telehealth providers, this research should prompt a hard look at set-and-setting guidance, real-time monitoring options, and how quickly clinical staff can respond if a patient has a difficult session. For patients evaluating programs, it's a checklist item: does this provider explain side effects in detail before I start, and is someone reachable if something feels wrong during my at-home session?
Screening Is the Variable That Changes the Equation
The patients most likely to discontinue NMDA antagonist therapy are those for whom it was a poor fit to begin with — individuals with uncontrolled hypertension, active psychosis, certain personality disorder presentations, or a history of substance misuse that wasn't surfaced during intake. This is where provider vetting becomes the most consequential decision a prospective patient makes.
Quality online ketamine programs don't just verify a depression diagnosis. They evaluate cardiac health, review current medications for dangerous interactions (particularly with other CNS depressants or MAOIs), assess dissociation tolerance and trauma history, and in many cases require coordination with a therapist or psychiatrist who will continue care between sessions. That level of screening is what separates a program likely to see low discontinuation and high patient satisfaction from one that inflates its patient volume at safety's expense.
The Psychiatric Times data reinforces a simple truth: ketamine's side effect profile is manageable and, for most patients, mild and short-lived — but only when the right patients are selected and supported appropriately.
Key Takeaway for Patients
Side effects from ketamine and esketamine are real but almost always temporary, resolving within hours of a session. The research suggests that discontinuation is more often a failure of preparation and screening than a signal that the treatment itself is unsafe. When evaluating an online ketamine provider, ask directly how they handle adverse reactions, who is reachable during your session, and what their intake evaluation covers. A program that can answer those questions clearly is one built around your safety — not just your sign-up.
Practical Takeaways for Anyone Considering Online Ketamine Treatment
- Expect the dissociation — don't be surprised by it. Any reputable provider will walk you through what a ketamine session feels like before you begin. If yours doesn't, that's a red flag.
- Cardiovascular screening isn't optional. Elevated blood pressure is one of the most consistent acute side effects across NMDA antagonists. Providers should be reviewing your cardiac history and current vitals, not skipping it.
- Follow-up matters as much as the session itself. Programs with structured integration support and clear escalation protocols are more likely to keep patients in treatment long enough to see lasting benefit.
- Discontinuation doesn't mean failure. If you've tried esketamine or ketamine before and stopped due to tolerability, that experience is worth sharing in detail with your next provider. Dose adjustments, pacing changes, and better preparation can make a significant difference.
The full analysis is available via Psychiatric Times. As the evidence base for NMDA antagonists continues to mature, research like this helps both patients and providers make better-informed decisions about who should start treatment, how it should be delivered, and what success actually looks like over time.
Share